Correspondence 0001104659-23-007453 from MetaVia Inc. (MTVA)
MetaVia Inc.
Date: Jan. 27, 2023 · CIK: 0001638287 · Accession: 0001104659-23-007453
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-369365
Letter
Re: NeuroBo Pharmaceuticals, Inc.
January 27, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention: Jimmy McNamara
Registration Statement on Form S-3
File No. 333-369365
Acceleration Request
Requested Date: January 31, 2023
Requested Time: 5:30 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-369365) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence, Samuel Katz and Garrett Packer of Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702, Samuel Katz of Honigman LLP by telephone at (313) 465-8137 or Garrett Packer of Honigman LLP by telephone at (313) 465-8090.
[Signature page follows]
****
Sincerely,
NeuroBo Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
January 27, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention: Jimmy McNamara
Re:
NeuroBo Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-369365
Acceleration Request
Requested Date:
January 31, 2023
Requested Time:
5:30 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rules 460 and
461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully
requests that the above-referenced Registration Statement on Form S-3 (File No. 333-369365) (the “Registration Statement”)
be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable
thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of
Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence, Samuel Katz and
Garrett Packer of Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness
of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702, Samuel Katz of Honigman LLP by telephone
at (313) 465-8137 or Garrett Packer of Honigman LLP by telephone at (313) 465-8090.
[Signature page follows]
****
Sincerely,
NeuroBo Pharmaceuticals, Inc.
/s/ Joseph Hooker
Joseph Hooker
Interim President and Chief Executive Officer
cc:
Phillip Torrence, Honigman LLP
Samuel Katz, Honigman LLP
Garrett Packer, Honigman LLP